SCHEMBL6674879

SCHEMBL6674879

CCc1nc(OC)c(N=C(NO)N2CCN(c3ccc(C)cc3)CC2)cc1C(=O)OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.39
GFER P55789 3/20 0.38
KMT2A Q03164 4/20 0.37
MEN1 O00255 2/20 0.37
LMNA P02545 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
MAPK1 P28482 2/20 0.37
GAA P10253 2/20 0.37
HTT P42858 2/20 0.37
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
THRB P10828 1/20 0.36
HSD17B10 Q99714 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ALDH1A1 P00352 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
DHFR P00374 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6678058 0.92 LMNA (0.34) MAPTKMT2AMEN1LMNASMN1; SMN2
SCHEMBL6679148 0.90 KMT2A (0.37) MAPTGFERKMT2AMEN1LMNA
SCHEMBL6673384 0.89 GAA (0.39) MAPTGFERKMT2AMEN1LMNA
SCHEMBL6678774 0.88 TP53 (0.36) MAPTKMT2AMEN1CYP2C9CYP2C19
SCHEMBL6672628 0.88 KMT2A (0.37) MAPTKMT2AMEN1LMNASMN1; SMN2
SCHEMBL6673420 0.86 KMT2A (0.36) MAPTKMT2ALMNAHTTNPC1
SCHEMBL6679250 0.85 DHFR (0.36) MAPTGFERLMNACYP2C19NPC1
SCHEMBL6673642 0.83 THRB (0.37) MAPTKMT2AMEN1LMNAHTT
SCHEMBL6675144 0.83 MAPT (0.39) MAPTGFERKMT2AMEN1LMNA
SCHEMBL6674884 0.82 GFER (0.40) MAPTGFERKMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1424072-A1 N'-(pyridin-3-yl)-(4-phenylpiperazin-1-yl)-carboxyimidamide and -iminothiolate derivatives for the treatment of tumors Samjin Pharmaceutical Co., Ltd. (KR) 2004-06-02 EP disclosed
US-6683184-B2 ANTITUMOR AGENTS SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2004-01-27 US disclosed
US-20030092910-A1 Piperazine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092910-A1 Piperazine derivatives and process for the preparation thereof CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS MAPT 4877/4885GFER 1199/4885KMT2A 2664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.